Buprenorphine Induction Protocol for Opioid Withdrawal
For patients with moderate-to-severe opioid withdrawal (COWS ≥8), initiate buprenorphine at 4-8 mg sublingual, titrate to a target dose of 16 mg daily, and prescribe for 3-7 days or until addiction treatment follow-up. 1
Timing of Initiation: The Critical Window
The most important factor in successful buprenorphine induction is waiting for objective signs of moderate withdrawal before administering the first dose to avoid precipitated withdrawal 1, 2. Due to buprenorphine's high binding affinity and partial agonist properties at the mu-opioid receptor, giving it too early will displace full agonists and trigger severe withdrawal symptoms 1.
Required waiting periods from last opioid use:
- Short-acting opioids (heroin, morphine IR, oxycodone IR): Wait >12 hours 1, 2
- Extended-release formulations (OxyContin): Wait >24 hours 1
- Methadone maintenance: Wait >72 hours (consider methadone instead of buprenorphine for these patients) 1, 2
Only initiate when COWS score ≥8 (moderate-to-severe withdrawal) 1. If COWS <8, reassess in 1-2 hours and do not give buprenorphine 1.
Initial Sublingual Dose
Give 4-8 mg sublingual buprenorphine based on withdrawal severity when COWS ≥8 1. The FDA label supports starting with 8 mg on Day 1 2. Reassess the patient after 30-60 minutes 1.
The initial dose can be given in 2-4 mg increments if preferred, though rapid titration to an adequate treatment dose is recommended to minimize dropout during induction 1, 2. Studies show gradual induction over several days led to high dropout rates 1, 2.
Dose Titration
Target 16 mg sublingual buprenorphine total on Day 1 for most patients 1. The FDA-approved protocol used in clinical trials administered 8 mg on Day 1 and 16 mg on Day 2, then continued 16 mg daily from Day 3 onward 2.
Maintenance dosing range: 4-24 mg daily, with 16 mg as the recommended target 2. Doses higher than 24 mg have not demonstrated clinical advantage 2. Adjust in 2-4 mg increments to suppress withdrawal symptoms and retain patients in treatment 2.
The evidence strongly supports buprenorphine over alternatives—it produces less severe withdrawal symptoms, fewer adverse effects, and better treatment retention compared to clonidine or lofexidine 1. Buprenorphine is similarly effective to tapered methadone but more practical for outpatient settings 1.
Tapering/Discharge Schedule
For X-waivered providers: Prescribe 16 mg sublingual buprenorphine/naloxone daily for 3-7 days or until follow-up appointment 1. The combination product with naloxone is preferred after induction to reduce diversion risk 2.
Sample 3-day prescription:
- Buprenorphine/naloxone 8 mg/2 mg sublingual tablet or film
- Take 2 tablets/films once daily in AM
- Dispense #6
- No refills 1
For non-X-waivered providers: Patients may return for up to 3 consecutive days for interim treatment under the 72-hour rule, which allows administration (but not prescription) of buprenorphine for acute withdrawal while arranging referral 1. Not more than one day's medication may be given at a time, and treatment cannot exceed 72 hours 1.
Critical Pitfalls to Avoid
Precipitated withdrawal is the primary risk 1, 3. This occurs when buprenorphine is given too soon after full agonist use, causing severe withdrawal that can be so distressing patients refuse further treatment 3. Patients on methadone >30 mg are particularly susceptible 2.
Do not prescribe multiple refills early in treatment without appropriate follow-up 2. Provision of take-home medication should consider the patient's stability and home security 2.
Complicating factors requiring modified approach: pregnancy, chronic opioid therapy for pain, anticipated surgery, concurrent alcohol/benzodiazepine intoxication, post-naloxone reversal, or serious acute medical illness 1.
Alternative Approaches for Complex Cases
Recent evidence supports low-dose initiation (microdosing) for patients who cannot tolerate traditional induction, particularly those using high-potency synthetic opioids like fentanyl 4, 5, 6. This involves starting with very low buprenorphine doses (0.5-2 mg) and gradually increasing over 3-4 days while continuing full agonist use, avoiding the need for withdrawal before initiation 4, 5. However, this approach is primarily supported by case series and requires close monitoring 4, 5, 6.
Harm Reduction Measures
Always provide:
- Overdose prevention education
- Take-home naloxone kit
- Hepatitis C and HIV screening
- Reproductive health counseling 1
Buprenorphine initiation in emergency departments has demonstrated better short-term improvement in treatment engagement and reduced illicit opioid use compared to referral alone 1. This approach saves lives by connecting patients to medication-assisted treatment at a critical access point 1.